Item 2.02 Results of Operations and Financial Condition
On October 23, 2019, Rigel Pharmaceuticals, Inc. (Rigel) announced certain preliminary financial results for its third quarter ended September 30, 2019. A copy of the press release titled Rigel Pharmaceuticals Provides Business Update Prior to Investor & Analyst Call, is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.
As previously disclosed on October 16, 2019, Rigel will host a conference call and webcast for investors and analysts on October 23, 2019 at 10:00 a.m. Eastern Time. As part of the call, Rigel intends to announce that, based upon its preliminary estimates, contract revenues from collaborations were $9.1 million for the three months ended September 30, 2019, and Rigel expects to end September 30, 2019 with approximately $107.5 million in cash, cash equivalents, and short-term investments.
The above estimates have been prepared by and is the responsibility of Rigels management. Rigel has not yet completed its closing process for the third quarter ended September 30, 2019. This information is preliminary, has not been audited and is subject to change upon completion of Rigels closing procedures. Additional information and disclosure would be required for a more complete understanding of Rigels financial position and results of operations as of and for the three and nine months ended September 30, 2019. Moreover, even if Rigels actual results are consistent with this preliminary estimate, this information may not be indicative of results or developments in subsequent periods.
The conference call and accompanying slides will be webcast live and can be accessed from Rigels website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.
The information in Item 2.02 this report, including Exhibit 99.1 hereto, shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Rigel Pharmaceuticals, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.